CDT

Conduit Pharmaceuticals Inc.
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$1.10M
P/E Ratio
—
EPS
$-2814.22
Beta
1.45
52W High
$1778.00
52W Low
$0.08
50-Day MA
$2.05
200-Day MA
$113.20
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage biopharmaceutical company focused on creating innovative therapies for oncology and rare diseases, targeting significant unmet medical needs. Utilizing its proprietary drug delivery technology, Conduit aims to improve the efficacy and safety of existing treatments, thereby enhancing patient outcomes and reducing adverse effects. Supported by a seasoned management team and strategic collaborations, the company is well-positioned to advance its pipeline of transformative products, with the potential to significantly influence the healthcare landscape.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-22.83M
Operating Margin0.00%
Return on Equity-69.70%
Return on Assets-23.40%
Revenue/Share (TTM)$0.00
Book Value$163.36
Price-to-Book0.02
Price-to-Sales (TTM)—
EV/Revenue-
EV/EBITDA-55.41
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$13.69M
Float343,920
% Insiders43.21%
% Institutions0.09%

Historical Volatility

HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—

Latest News

CDT Equity Inc. Announces Reverse Stock Split

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.

GlobeNewsWire9/25/2026Neutral
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds.

GlobeNewsWire8/28/2026Neutral
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a SAFE note with Pep'd Inc. (“Pep'd”), a US-based peptide company, expanding CDT's exposure to the growing US peptide market (the “Transaction”).

GlobeNewsWire8/25/2026Neutral
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that it has entered into a strategic transaction to increase its equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors, to 22.7% through the issuance of pre-funded warrants to purchase up to 12,131,770 shares of the Company's common stock, subject to shareholder approval at the Company's annual meeting of stockholders on August 28, 2026 (the “Transaction”).

GlobeNewsWire8/3/2026Neutral
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane

NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new patent application covering a large set of field-deployable, two-component combination interventions for sugarcane cultivation, generated through Sarborg's quantum-enabled PRISM platform.

GlobeNewsWire7/20/2026Neutral
CDT Equity Inc. Announces Reverse Stock Split

NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-10 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule.

GlobeNewsWire7/16/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDT and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/26/2026